Read the April 2018 issue in its entirety.
With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.
The 2017 numbers aren't kind to print-first publishers. Is this a blip in print's fortunes or the start of a long-predicted decline?
Alok Sonig, chief executive officer of developed markets at Dr. Reddy's Laboratories, articulates the benefits of generics.
Read the March 2018 issue in its entirety.
We considered pharma and healthcare ads that, per iSpotTV, started airing no earlier than January 2017.
Following massive strikes by Opdivo and Keytruda, will more supersized campaigns follow?
Caregivers and patients predict how the use of AI will affect them.
In an unusual twist, the makers of cholesterol drug Praluent are re-pricing the treatment to align with the nonprofit's recommendation. Is industry warming to ICER?
Pharma companies are likely to put up aggressive resistance to the measure, introduced earlier this month.
AI's marketing problem: Inflated claims, outsized expectations may actually be slowing AI's move into clinical practice
The potential is real, but companies and technology gurus often speak of machine learning as a catch-all solution. The hype may be slowing AI's incremental growth in healthcare, experts say.
MM&M has announced its annual showcase of executives, investors, entrepreneurs, designers and thinkers who are ushering the industry into its new technological golden era.
Want to get an ethicist agitated? Mention the integration of voice-activation and other tech into healthcare. Experts say navigating this area is a work in progress.
Now more than ever, patients aren't shy about sharing their wants and needs. Here, 8,000 patients from three generations in the U.S., U.K., Germany, and France weigh in on everything from brand loyalty to the factors that drive their decision-making-processes to the reasons they switch treatments.
As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.
When Ortho Clinical Diagnostics lived under the roof of Johnson & Johnson, it had the luxury of focusing on its product and service mix — and not a whole lot else.
Pharma has backed a number of AR-based games for physician learning and marketing. They're meant to complement live learning, but mobile games may do a better job teaching certain skills.
The general sense: Nobody should get comfortable with the status quo
Read the February 2018 issue in its entirety.
The new HHS secretary has been given a difficult task by President Trump: bring drug prices down.
There was so much bigger-picture coverage of pharma and healthcare in 2017 - pricing, Affordable Care Act reform and repeal - that it was easy to lose sight of everything else. PwC's Health Research Institute has used its annual look-ahead report to spotlight a handful of undercover trends.
More has been written about millennials — and their healthcare habits — than about any other generation. Here, Gen Y marketers explain why most of what you've read is wrong.
Zero people have such tales about Robert Leverte, which is why news of his pending induction into the Medical Advertising Hall of Fame was received warmly when it was made public last October.
We asked some of the agency world's sharpest data people to answer a pair of questions about the future of data in and around pharma marketing. Here's what they had to say.
In the past, pharma hasn't used data effectively to engage its A-list HCPs. Five companies hope to change that.
Fueled by system-wide demand and facilitated by AI, the industry's lofty expectations around real-world evidence could soon be fulfilled
Spark has priced its cure for a rare form of blindness at $425,000 per eye. But rather than the science or the cost, pharma is buzzing over the company's outcomes-based pricing model
Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.
Four data aces share their backgrounds, inspirations, and guiding philosophies
Read the January 2018 issue in its entirety.
Clayman says the company's next 18 months are all about Zilretta, with further pipeline construction next up.
Not only isn't print dead, as ahead-of-themselves media wonks have claimed for the past decade, but it's thriving in a most unlikely environment: the point of care
For all the talk about new and better ways to engage, pharma still hasn't created an appreciably higher volume of satisfied — or informed — customers.
In the absence of behemoths such as Facebook and Twitter, pharma is partnering with China's tech giants to snare a slice of a more than $100 billion market
Do the healthcare and pharma arms of Accenture, Deloitte, PwC, and other consultancies pose an existential threat to traditional healthcare agencies?
The group's reports, received with great interest by insurers and the Department of Veteran Affairs, have concluded certain high-profile drugs aren't worth the cost. Pharma still hasn't decided whether ICER is friend or foe.
Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."
Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.
Innovation-minded executives share their thoughts and predictions for the year ahead.
The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.
Read the December 2017 issue in its entirety.
Read the November 2017 issue in its entirety.
To remain relevant, speakers bureaus must evolve to a strategic marketing tactic with personalized messaging to the customer.
Second to market and dismissed as inferior to the competition, Sanofi's Aubagio seemed destined for lower-tier status. Here's how it overcame the initial obstacles and, five years later, become a potent market force
This year's offering includes access to the most current and in-depth data on salary and compensation trends, job satisfaction, recruitment and retention tactics, and more.
Read the October 2017 issue in its entirety, including our Career and Salary Survey.
The top three most advertised brands were GlaxoSmithKline's Breo Ellipta, Eli Lilly's Trulicity, and Boehringer Ingelheim's Jardiance.
The successes of these pharma execs show that there's no one path to professional bliss.
Now that Facebook, Apple, and Google have set their sights on healthcare, agencies find themselves under pressure from yet another flank.
Salaries are up — by a lot — and marketers are enthusiastic about their career prospects.
Read the September 2017 issue in its entirety, including how marketing can save clinical trials.
The answer: it depends on what phase the trial is in.
Still, most experts characterize this year's newly approved women's health drugs as modest improvements rather than groundbreaking advances in medicine.
Amgen's Prolia tops the list, according to data compiled by EvaluatePharma.
The best marketers possess a mix of scientific know-how, digital dexterity, and unflappability. To keep them, agencies need to revise their thinking and tactics.
No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
Alone among the best-known social platforms, Snapchat has failed to generate much enthusiasm from pharma. Here's why — and here's why that may change.
Read the August 2017 issue in its entirety, including our recap of the MM&M Hall of Femme event.
Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?
Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.
He was diagnosed years ago with a handful of autoimmune conditions, treating them with drugs like Abbvie's Humira, which he helped commercialize.
Two recent cash infusions suggest investors are bullish on point-of-care advertising. Is the channel ready for its moment in the spotlight?
Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.
Patients are demanding more of their healthcare experience — and that includes from their healthcare providers, according to two new surveys.
Pharma has more or less ignored the social-blog hybrid Tumblr, with the number of programs using it countable on a single hand. That's about to change.
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.
Participants in this roundtable explore how digital forms of data are poised to illuminate the reimbursement pathway, as market access gets its closeup.
Susan Sweeney has earned a reputation for such pragmatism and attentiveness to the things that really matter.
Read the 2017 Agency Issue in its entirety.
Meet 13 of our 16 Hall of Femme honorees.
Frustrated by its inability to empathize with patients, pharma has turned to tech to teach providers and caregivers what illness really feels like.
McCann Health, Cannes Lions Healthcare Network of the Year, hosted a roundtable to discuss the role of creativity in a new world order where populism is undermining trust.
Here are nine agencies that are gaining traction in healthcare marketing.
Discover how M&A activity in 2016 and 2017 has reshaped North American healthcare agencies and the holding companies that own them.
Here you'll find the last four years of the MM&M Agency Issue.
Healthcare networks instigated a broad set of changes in a grand embrace of non-pharma business that diversified revenue streams and took specialist agencies out of their comfort zones.
Havas Health & You, WPP Health & Wellness, and Klick Health reported the highest revenue last year.
The CEOs of the industry's largest holding companies discuss how they're reasserting their businesses.
Read on for more about the top performing firms, the trends shaping the business, and the story behind each of the top 100 agencies.
Here you'll find everything from the Patient Journey 2017 supplement to our June issue.
Here you'll find everything from our June 2017 issue, including our Pharma Report, our Hall of Femme, and two roundtable discussions on media and oncology.
In apportioning their media budgets, pharma companies continue to straddle the line between new and traditional strategies.
Industry leaders discussed why a social-centric approach is especially important in oncology, particularly as it relates to health systems, interactions with healthcare providers, and family support.
Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
Five sector pros discuss adapting to patient-centricity and how pinpointing patient needs leads to success.
Here you'll find everything from our May 2017 issue, including our Top 40 Transformers, deep dive into autoimmune drugs, and more.
Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.
Here you'll find Sara Holoubek's deep dive into how pharma is tackling some of its biggest challenges.
Under Duato, the leadership team for Johnson & Johnson's pharma group includes six women. "We don't just talk about it," he says.
Researchers still don't know why Americans who are prescribed a prescription drug to treat a chronic condition or disease so often fail to fill those prescriptions.
Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.
While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.
AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.
Here you'll find everything you need to know from MM&M's April 2017 issue, including our DTC report, our deep dive into respiratory drugs, and more.
How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?
For the second year, MM&M is honoring 16 of the most-senior women in the healthcare industry.
A tool kit of pharma case studies and advice for healthcare brands in making behavioral science a foundational part of a marketing strategy.
MM&M honors 40 upstarts and veteran innovation gurus.